Brand Name(s):Torisel
Indication:All licensed indications
Rationale:2
Considered:Oct-06
Review Date:Jan-26
Comments:
NICE is unable to recommend the use in the NHS of temsirolimus for the
treatment of relapsed or refractory mantle cell lymphoma because no
evidence submission was received from the manufacturer or sponsor of
the technology.
NICE TA207
Temsirolimus for the treatment of relapsed or refractory mantle cell
lymphoma (terminated appraisal) October 2010
Bevacizumab, sorafenib and temsirolimus are not recommended as first-line treatment options for people with advanced and/or metastatic renal cell carcinoma.
People who are currently being treated with bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for advanced and/or metastatic renal cell carcinoma should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.
NICE TA 178
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma August 2009
Severe infusion-related hypersensitivity reactions have occurred in patients
receiving temsirolimus. Patients must be closely monitored throughout infusion,
and appropriate supportive care should be available
MHRA Drug safety update Volume 2, Issue 6 January 2009